MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects, best way to give, and best dose of Akt
inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or
leukemia. MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.